201 related articles for article (PubMed ID: 16036915)
1. Dominant negative mechanism underlies autosomal dominant Stargardt-like macular dystrophy linked to mutations in ELOVL4.
Grayson C; Molday RS
J Biol Chem; 2005 Sep; 280(37):32521-30. PubMed ID: 16036915
[TBL] [Abstract][Full Text] [Related]
2. Atrophic macular degeneration mutations in ELOVL4 result in the intracellular misrouting of the protein.
Ambasudhan R; Wang X; Jablonski MM; Thompson DA; Lagali PS; Wong PW; Sieving PA; Ayyagari R
Genomics; 2004 Apr; 83(4):615-25. PubMed ID: 15028284
[TBL] [Abstract][Full Text] [Related]
3. Loss of ER retention and sequestration of the wild-type ELOVL4 by Stargardt disease dominant negative mutants.
Karan G; Yang Z; Howes K; Zhao Y; Chen Y; Cameron DJ; Lin Y; Pearson E; Zhang K
Mol Vis; 2005 Aug; 11():657-64. PubMed ID: 16145543
[TBL] [Abstract][Full Text] [Related]
4. Mutant ELOVL4 that causes autosomal dominant stargardt-3 macular dystrophy is misrouted to rod outer segment disks.
Agbaga MP; Tam BM; Wong JS; Yang LL; Anderson RE; Moritz OL
Invest Ophthalmol Vis Sci; 2014 May; 55(6):3669-80. PubMed ID: 24833735
[TBL] [Abstract][Full Text] [Related]
5. A novel mutation in the ELOVL4 gene causes autosomal dominant Stargardt-like macular dystrophy.
Maugeri A; Meire F; Hoyng CB; Vink C; Van Regemorter N; Karan G; Yang Z; Cremers FP; Zhang K
Invest Ophthalmol Vis Sci; 2004 Dec; 45(12):4263-7. PubMed ID: 15557430
[TBL] [Abstract][Full Text] [Related]
6. Stargardt-like macular dystrophy protein ELOVL4 exerts a dominant negative effect by recruiting wild-type protein into aggresomes.
Vasireddy V; Vijayasarathy C; Huang J; Wang XF; Jablonski MM; Petty HR; Sieving PA; Ayyagari R
Mol Vis; 2005 Aug; 11():665-76. PubMed ID: 16163264
[TBL] [Abstract][Full Text] [Related]
7. Expression of wild type and mutant ELOVL4 in cell culture: subcellular localization and cell viability.
Karan G; Yang Z; Zhang K
Mol Vis; 2004 Mar; 10():248-53. PubMed ID: 15073583
[TBL] [Abstract][Full Text] [Related]
8. Deciphering mutant ELOVL4 activity in autosomal-dominant Stargardt macular dystrophy.
Logan S; Agbaga MP; Chan MD; Kabir N; Mandal NA; Brush RS; Anderson RE
Proc Natl Acad Sci U S A; 2013 Apr; 110(14):5446-51. PubMed ID: 23509295
[TBL] [Abstract][Full Text] [Related]
9. Dominant Stargardt Macular Dystrophy (STGD3) and ELOVL4.
Logan S; Anderson RE
Adv Exp Med Biol; 2014; 801():447-53. PubMed ID: 24664730
[TBL] [Abstract][Full Text] [Related]
10. Genetics and molecular pathology of Stargardt-like macular degeneration.
Vasireddy V; Wong P; Ayyagari R
Prog Retin Eye Res; 2010 May; 29(3):191-207. PubMed ID: 20096366
[TBL] [Abstract][Full Text] [Related]
11. Elovl4 5-bp deletion knock-in mouse model for Stargardt-like macular degeneration demonstrates accumulation of ELOVL4 and lipofuscin.
Vasireddy V; Jablonski MM; Khan NW; Wang XF; Sahu P; Sparrow JR; Ayyagari R
Exp Eye Res; 2009 Dec; 89(6):905-12. PubMed ID: 19682985
[TBL] [Abstract][Full Text] [Related]
12. Endoplasmic reticulum microenvironment and conserved histidines govern ELOVL4 fatty acid elongase activity.
Logan S; Agbaga MP; Chan MD; Brush RS; Anderson RE
J Lipid Res; 2014 Apr; 55(4):698-708. PubMed ID: 24569140
[TBL] [Abstract][Full Text] [Related]
13. A novel gene for autosomal dominant Stargardt-like macular dystrophy with homology to the SUR4 protein family.
Edwards AO; Donoso LA; Ritter R
Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2652-63. PubMed ID: 11581213
[TBL] [Abstract][Full Text] [Related]
14. Stargardt Phenotype Associated With Two ELOVL4 Promoter Variants and ELOVL4 Downregulation: New Possible Perspective to Etiopathogenesis?
Donato L; Scimone C; Rinaldi C; Aragona P; Briuglia S; D'Ascola A; D'Angelo R; Sidoti A
Invest Ophthalmol Vis Sci; 2018 Feb; 59(2):843-857. PubMed ID: 29417145
[TBL] [Abstract][Full Text] [Related]
15. Hetero-oligomeric interactions of an ELOVL4 mutant protein: implications in the molecular mechanism of Stargardt-3 macular dystrophy.
Okuda A; Naganuma T; Ohno Y; Abe K; Yamagata M; Igarashi Y; Kihara A
Mol Vis; 2010 Nov; 16():2438-45. PubMed ID: 21139992
[TBL] [Abstract][Full Text] [Related]
16. Association of adipose and red blood cell lipids with severity of dominant Stargardt macular dystrophy (STGD3) secondary to an ELOVL4 mutation.
Hubbard AF; Askew EW; Singh N; Leppert M; Bernstein PS
Arch Ophthalmol; 2006 Feb; 124(2):257-63. PubMed ID: 16476896
[TBL] [Abstract][Full Text] [Related]
17. A novel ELOVL4 variant, L168S, causes early childhood-onset Spinocerebellar ataxia-34 and retinal dysfunction: a case report.
Gyening YK; Boris K; Cyril M; Brush RS; Nassogne MC; Agbaga MP
Acta Neuropathol Commun; 2023 Aug; 11(1):131. PubMed ID: 37568198
[TBL] [Abstract][Full Text] [Related]
18. Role of ELOVL4 and very long-chain polyunsaturated fatty acids in mouse models of Stargardt type 3 retinal degeneration.
Barabas P; Liu A; Xing W; Chen CK; Tong Z; Watt CB; Jones BW; Bernstein PS; Križaj D
Proc Natl Acad Sci U S A; 2013 Mar; 110(13):5181-6. PubMed ID: 23479632
[TBL] [Abstract][Full Text] [Related]
19. Diverse macular dystrophy phenotype caused by a novel complex mutation in the ELOVL4 gene.
Bernstein PS; Tammur J; Singh N; Hutchinson A; Dixon M; Pappas CM; Zabriskie NA; Zhang K; Petrukhin K; Leppert M; Allikmets R
Invest Ophthalmol Vis Sci; 2001 Dec; 42(13):3331-6. PubMed ID: 11726641
[TBL] [Abstract][Full Text] [Related]
20. ELOVL4: Very long-chain fatty acids serve an eclectic role in mammalian health and function.
Hopiavuori BR; Anderson RE; Agbaga MP
Prog Retin Eye Res; 2019 Mar; 69():137-158. PubMed ID: 30982505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
